Safety of intravitreally administered recombinant erythropoietin (an AOS thesis)

Transactions of the American Ophthalmological Society

Volumn 106, Issue , 2008, Pages 459-472

  Tsai, James C ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; B WAVE; CELL DENSITY; CONTROLLED STUDY; DRUG SAFETY; ELECTRORETINOGRAPHY; EYE TOXICITY; HISTOLOGY; INTRAOCULAR PRESSURE; LATENT PERIOD; MALE; MICROSCOPY; NIGHT VISION; NONHUMAN; PRIORITY JOURNAL; RAT; RETINA GANGLION CELL; RETINA ROD; STAINING; THICKNESS; ANIMAL; DRUG EFFECT; INJECTION; PATHOLOGY; PILOT STUDY; RETINA; SPRAGUE DAWLEY RAT; VITREOUS BODY;

ANIMALS; ELECTRORETINOGRAPHY; ERYTHROPOIETIN, RECOMBINANT; INJECTIONS; INTRAOCULAR PRESSURE; MALE; PILOT PROJECTS; RATS; RATS, SPRAGUE-DAWLEY; RETINA; RETINAL GANGLION CELLS; VITREOUS BODY;

EID: 63049085230     PISSN: None     EISSN: 15456110     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. Friedman DS, Wolfs RC, O'Colmain BJ, et al. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol 2004;122:532-538.
2. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006;90:262-267.
3. Allingham RR, Damji K, Freedman S, Moroi S, Shafranov. Shields' Textbook of Glaucoma. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2005:73-115.
4. McKendrick AM, Sampson GP, Walland MJ, Badcock DR. Contrast sensitivity changes due to glaucoma and normal aging: low-spatial-frequency losses in both magnocellular and parvocellular pathways. Invest Ophthalmol Vis Sci 2007;48:2115-122.
5. Gupta N, Ang LC, Noel de Tilly L, Bidaisee L, Yücel YH. Human glaucoma and neural degeneration in intracranial optic nerve, lateral geniculate nucleus, and visual cortex. Br J Ophthalmol 2006;90:674-678.
6. Tsai JC, Forbes M. Medical Management of Glaucoma. 2nd ed. Caddo, OK: Professional Communications; 2004:79-112.
7. Collaborative Normal Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 1998;126:487-497.
8. Anderson DR; Normal Tension Glaucoma Study Group. Collaborative normal tension glaucoma study. Curr Opin Ophthalmol 2003;14: 86-90.
9. Drance S, Anderson DR, Schulzer M; Collaborative Normal-Tension Glaucoma Study Group. Risk factors for progression of visual field abnormalities in normal-tension glaucoma. Am J Ophthalmol 2001;131:699-708.
10. Lipton SA. Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and Snitrosylation. Curr Drug Targets 2007;8:621-632.
11. Yücel YH, Gupta N, Zhang Q, Mizisin AP, Kalichman MW, Weinreb RN. Memantine protects neurons from shrinkage in the lateral geniculate nucleus in experimental glaucoma. Arch Ophthalmol 2006;124:217-225.
12. Neufeld AH. Pharmacologic neuroprotection with an inhibitor of nitric oxide synthase for the treatment of glaucoma. Brain Res Bull 2004;62:455-459.
13. Brines M, Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci 2005;6:484-494.
14. Bakalash S, Shlomo GB, Aloni E, et al. T-cell-based vaccination for morphological and functional neuroprotection in a rat model of chronically elevated intraocular pressure. J Mol Med 2005;83:904-916.
15. Thanos C, Emerich D. Delivery of neurotrophic factors and therapeutic proteins for retinal diseases. Expert Opin Biol Ther 2005;5:1443-1452.
16. Sieving PA, Caruso RC, Tao W, et al. Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc Natl Acad Sci U S A 2006;103:3896-3901.
17. Guo L, Salt TE, Luong V, et al. Targeting amyloid-beta in glaucoma treatment. Proc Natl Acad Sci U S A 2007;104:13444-13449.
18. Das A, Garner DP, Del Re AM, et al. Calpeptin provides functional neuroprotection to rat retinal ganglion cells following Ca2+ influx. Brain Res 2006;1084:146-157.
19. Levkovitch-Verbin H, Kalev-Landoy M, Habot-Wilner Z, Melamed S. Minocycline delays death of retinal ganglion cells in experimental glaucoma and after optic nerve transaction. Arch Ophthalmol 2006;124:520-526.
20. Yang LP, Li Y, Zhu XA, Tso MO. Minocycline delayed photoreceptor death in rds mice through iNOS-dependent mechanism. Mol Vis 2007;13:1073-1082.
21. Neufeld AH, Sawada A, Becker B. Inhibition of nitric-oxide synthase 2 by aminoguanidine provides neuroprotection of retinal ganglion cells in a rat model of chronic glaucoma. Proc Natl Acad Sci U S A 1999;96:9944-9948.
22. Tsai JC, Song BJ, Wu L, Forbes M. Erythropoietin: a candidate neuroprotective agent in the treatment of glaucoma. J Glaucoma 2007;16:567-571.
23. Richmond TD, Chohan M, Barber DL. Turning cells red: signal transduction mediated by erythropoietin. Trends Cell Biol 2005;15:146-155.
24. Genc S, Akhisaroglu M, Kuralay F, Genc K. Erythropoietin restores glutathione peroxidase activity in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine- induced neurotoxicity in C57BL mice and stimulates murine astroglial glutathione peroxidase production in vitro. Neurosci Lett 2002;321:73-76.
25. Maurer MH, Frietsch T, Waschke KF, Kuschinsky W, Gassmann M, Schneider A. Cerebral transcriptome analysis of transgenic mice overexpressing erythropoietin. Neurosci Lett 2002;3:181-184.
26. Sirén AL, Ehrenreich H. Erythropoietin - a novel concept for neuroprotection. Eur Arch Psychiatry Clin Neurosci 2001;251:179-184.
27. Farrell F, Lee A. The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist 2004;9 Suppl 5:18-30.
28. Bernaudin M, Marti HH, Roussel S, et al. A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metabol 1999;19:643-651.
29. Sirén AL, Radyushkin K, Boretius S, et al. Global brain atrophy after unilateral parietal lesion and its prevention by erythropoietin. Brain 2006;129:480-489.
30. Kaptanoglu E, Solaroglu I, Okutan O, Surucu HS, Akbiyik F, Beskonakli E. Erythropoietin exerts neuroprotection after acute spinal cord injury in rats: effect on lipid peroxidation and early ultrastructural findings. Neurosurg Rev 2004;27:113-120.
31. Campana WM, Myers RR. Exogenous erythropoietin protects against dorsal root ganglion apoptosis and pain following peripheral nerve injury. European Journal of Neuroscience 2003; 18:1497-506.
32. Sekiguchi Y, Kikuchi S, Myers RR, Campana WM. ISSLS prize winner: Erythropoietin inhibits spinal neuronal apoptosis and pain following nerve root crush. Spine 2003; 28: 2577-84.
33. Smith RE, Jr. Erythropoietic agents in the management of cancer patients. Part 2: studies on their role in neuroprotection and neurotherapy. Journal of Supportive Oncology 2004; 2:39
34. Brines M, Grasso G, Fiordaliso F, et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci U S A 2004;101:14907-14912.
35. Leist M, Ghezzi P, Grasso G, et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004;305:239-242.
36. Digicaylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 2001;412:641-647.
37. Kawakami M, Sekiguchi M, Sato K, Kozaki S, Takahashi M. Erythropoietin receptor-mediated inhibition of exocytotic glutamate release confers neuroprotection during chemical ischemia. J Bio Chem 2001;276:39469- 39475.
38. Weishaupt J, Rohde G, Pölking E, et al. Effect of erythropoietin axotomy-induced apoptosis in rat retinal ganglion cells. Invest Ophthalmol Vis Sci 2004;45:1514-1522.
39. Malhotra S, Savitz SI, Ocava L, Rosenbaum DM. Ischemic preconditioning is mediated by erythropoietin through PI-3 kinase signaling in an animal model of transient ischemic attack. J Neurosci Res 2006;83:19-27.
40. Digicaylioglu M, Garden G, Timberlake S, Fletcher L, Lipton SA. Acute neuroprotective synergy of erythropoietin and insulin-like growth factor I. Proc Natl Acad Sci U S A 2004;101:9855-9860.
41. Sättler MB, Merkler D, Maier K, et al. Neuroprotective effects and intracellular signaling pathways of erythropoietin in a rat model of multiple sclerosis. Cell Death Differ 2004;11 Suppl 2:S181-S192.
42. Morrison J, Farrell S, Johnson E, Deppmeier L, Moore CG, Grossmann E. Structure and composition of the rodent lamina cribrosa. Exp Eye Res 1995;60:127-135.
43. Junk AK, Mammis A, Savitz SI, et al. Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc Natl Acad Sci U S A 2002;99:10659-10664.
44. Tsai JC, Wu L, Worgul B, Forbes M, Cai J. Intravitreal administration of erythropoietin and preservation of retinal ganglion cells in an experimental rat model of glaucoma. Curr Eye Res 2005;30:1025-1031.
45. van der Meer P, Voors A, Lipsic E, Smilde T, van Gilst W, van Veldhuisen D. Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J Am Coll Cardiol 2004;44:63-67.
46. Henry D, Bowers P, Romano M, Provenzano R. Epoetin alfa: clinical evolution of a pleiotropic cytokine. Arch Intern Med 2004;164:262-276.
47. Stockmann C, Fandrey J. Hypoxia-induced erythropoietin production: a paradigm for oxygen-regulated gene expression. Clin Exp Pharmacol Physiol 2006;33:968-979.
48. Watanabe D, Suzuma K, Matsui S, et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med 2005;353:782-792.
49. Ribatti D. A potential role of erythropoietin in angiogenesis associated with myelodysplastic syndromes. Leukemia 2002;16:1890; author reply 1891.
50. Ribatti D, Marzullo A, Nico B, Crivellato E, Ria R, Vacca A. Erythropoietin as an angiogenic factor in gastric carcinoma. Histopathology 2003;42:246-250.
51. Ribatti D, Vacca A, Dammacco F, English D. Angiogenesis and anti-angiogenesis in hematological malignancies. J Hematother Stem Cell Res 2003;12:11-22.
52. Yasuda Y, Fujita Y, Matsuo T, et al. Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 2003;24:1021-1029 [erratum appears in Carcinogenesis 2003;24:1567].
53. Rakusan K, Cicutti N, Kolar F. Cardiac function, microvascular structure, and capillary hematocrit in hearts of polycythemic rats. Am J Physiol Heart Circ Physiol 2001;281:H2425-H2431.
54. Jaquet K, Krause K, Tawakol-Khodai M, Geidel S, Kuck KH. Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res 2002;64:326-333.
55. Nakamatsu K, Nishimura Y, Suzuki M, Kanamori S, Maenishi O, Yasuda Y. Erythropoietin/erythropoietin-receptor system as an angiogenic factor in chemically induced murine hepatic tumors. Int J Clin Oncol 2004;9:184-188.
56. Di Raimondo F, Azzaro MP, Palumbo G, et al. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood. Haematologica 2000;85:800-805.
57. Hale SA, Wong C, Lounsbury KM. Erythropoietin disrupts hypoxia-inducible factor signaling in ovarian cancer cells. Gynecol Oncol 2006;100:14-19.
58. Hardee ME, Kirkpatrick JP, Shan S, et al. Human recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesis. Br J Cancer 2005;93:1350-1355.
59. Zhong L, Bradley J, Schubert W, et al. Erythropoietin promotes survival of retinal ganglion cells in DBA/2J glaucoma mice. Invest Ophthalmol Vis Sci 2007;48:1212-1218.
60. King CE, Rodger J, Bartlett C, Esmaili T, Dunlop SA, Beazley LD. Erythropoietin is both neuroprotective and neuroregenerative following optic nerve transection. Exp Neurol 2007;205:48-55.
61. Fu QL, Wu W, Wang H, Li X, Lee VW, So KF. Up-regulated endogenous erythropoietin/erythropoietin receptor system and exogenous erythropoietin rescue retinal ganglion cells after chronic ocular hypertension. Cell Mol Neurobiol 2008;28:317-329 (Epub 2007 Jun 7).
62. Garcia-Valenzuela E, Shareef S, Walsh J, Sharma SC. Programmed cell death of retinal ganglion cells during experimental glaucoma. Exp Eye Res 1995;61:33-44.
63. Mittag TW, Danias J, Pohorenec G, et al. Retinal damage after 3 to 4 months of elevated intraocular pressure in a rat glaucoma model. Invest Ophthalmol Vis Sci 2000;41:3451-3459
64. Sakanaka M, Wen T-C, Matsuda S, et al. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci U S A 1998;95:4635-4640.
65. Fortune B, Bui BV, Morrison JC, et al. Selective ganglion cell functional loss in rats with experimental glaucoma. Invest Ophthalmol Vis Sci 2004;45:1854-1862.
66. Bui BV, Fortune B. Ganglion cell contributions to the rat full-field electroretinogram. J Physiol 2004;555:153-173.
67. Schuettauf F, Eibl K, Thaler S, et al. Toxicity study of erucylphosphocholine in a rat model. Curr Eye Res 2005;30:813-20.
68. Saito S, Ohashi M, Naito A, et al. Neuroprotective effect of the novel Na+/Ca2+ channel blocker NS-7 on rat retinal ganglion cells. Jpn J Ophthalmol 2005;49:371-376.
69. Bui BV, Edmunds B, Cioffi GA, Fortune B. The gradient of retinal functional changes during acute intraocular pressure elevation. Invest Ophthalmol Vis Sci 2005;46:202-213.
70. Buemi M, Cavallaro E, Floccari F, et al. Erythropoietin and the brain: from neurodevelopment to neuroprotection. Clin Sci (Lond) 2002;103:275-282.
71. Dureau P, Bonnel S, Menasche M, Dufier JL, Abitbol M. Quantitative analysis of intravitreal injections in the rat. Curr Eye Res 2001;22:74-77.
72. Salomao SR, Watanabe SE, Berezovsky A, Motono M. Multifocal electretinography, color discrimination, and ocular toxicity in tamoxifen use. Curr Eye Res 2007;32:345-352.
73. Cordeiro MF, Guo L, Luong V, et al. Real-time imaging of single cell apoptosis in retinal neurodegeneration. Proc Natl Acad Sci U S A 2004;101:13352-13356.
74. Efthimiadou A, Pagonopoulou O, Lambropoulou M, et al. Erythropoietin enhances angiogenesis in an experimental cyclosporine A-induced nephrotoxicity model in the rat. Clin Exp Pharmacol Physiol 2007;34:866-869.
75. Brumm MV, Nguyen QD. Fluocinolone acetonide intravitreal sustained release device - a new addition to the armamentarium of uveitic management. Int J Nanomed 2007;2:55-64.
76. Kumar S. Nanoophthalmology: new frontier in fighting blindness? Eye 2006;20:1455-1456.